Comparison
Magnesium L-Threonate vs Memantine (Namenda)
Magnesium L-Threonate
MIT-developed magnesium that crosses the blood-brain barrier. Shown to enhance synaptic density and reduce 'brain age'.
Memantine (Namenda)
Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease. Reduces glutamate excitotoxicity while preserving normal signaling.
| Field | Magnesium L-Threonate | Memantine (Namenda) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–2000mg | 5–20mg |
| Half-life | 6h | 70h |
| Onset | — | 180min |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 90 | 4200 |
The comparison in plain English
Auto-generated from dataMagnesium L-Threonate and Memantine (Namenda) are both in the neuroprotective category respectively. Magnesium L-Threonate MIT-developed magnesium that crosses the blood-brain barrier. Memantine (Namenda) Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease.
Bottom line
Magnesium L-Threonate (evidence B, safety 5/5) has a stronger evidence base than Memantine (Namenda) (evidence A, safety 4/5). Magnesium L-Threonate has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Magnesium L-Threonate if
Magnesium L-Threonate is the better fit when your goal aligns with its mechanism (L-threonate is a sugar-acid carrier that uniquely enables magnesium to cross the blood-brain barrier in meaningful quantities — most oral magnesium forms (oxide, citrate, glycinate) raise serum magnesium but not central magnesium) and the dose range (1000–2000mg) suits your protocol. Half-life is 6h.
Choose Memantine (Namenda) if
Memantine (Namenda) is the better fit when your goal aligns with its mechanism (Uncompetitive NMDA receptor antagonist — blocks the NMDA channel only when it's pathologically over-activated, sparing normal signaling) and the dose range (5–20mg) suits your protocol. Half-life is 70h.